Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Middle East Respiratory Syndrome coronavirus S Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...
-
Dublin, June 09, 2022 (GLOBE NEWSWIRE) -- The "Human SARS coronavirus Spike Glycoprotein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players"...
-
Dublin, May 19, 2022 (GLOBE NEWSWIRE) -- The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...
-
Global In-Silico Drug Discovery Market to 2031 - Focus on Product, Workflow, Technology and End-user
Dublin, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The "In-Silico Drug Discovery Market: Focus on Product, Workflow, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to...
-
Dublin, Nov. 25, 2021 (GLOBE NEWSWIRE) -- The "Toxicology Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. According to analysis, the global...
-
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "microRNA 21 (MIR21) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering. microRNA 21 (MIR21) - Drugs in...
-
Dublin, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The "New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019-2025" report has been added to...
-
VANCOUVER, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
-
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
-
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...